Autism and Obsessive Compulsive Spectrum Program

Obsessive Compulsive Spectrum Disorders

1. Efficacy and Safety Study of Low-Dose Ondansetron (Serotonin-3 Receptor Antagonist) For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder 

**note: this study has completed**

Patients with Obsessive-Compulsive Disorder (OCD) can suffer from a broad range of functional and health-related quality of life domains. Chronic OCD can interfere with social and professional responsibilities, preventing patients from seeking medical care or even connective with family. Serotonin reuptake inhibitors (SRIs), drugs often prescribed for the treatment of OCD, do not work for about 40% of patients.

The drug Ondansetron (brand name: Zofran) is usually prescribed to ameliorate nausea and vomiting during chemotherapy. However, it is also reported to believed to act on dopamine pathways that could, combined with an SRI, be used as treatment for patients with OCD. This study aims to assess the efficacy and safety of low doses of Ondansetron (.5mg and .75mg) in conjunction with regimented SRI treatments. Combined at the correct doses, Ondansetron and an existing SRI may provide much needed treatment for patients with OCD.

If you or your child are interested in participating in this study, please contact Emma Racine at 718-653-4859 ext 223 or eracine@montefiore.org 

  

2. Fluoxetine in Pediatric Body Dysmorphic Disorder 

**note: this study has completed**

Body dysmorphic disorder (BDD)--a preoccupation with an imagined or slight defect in appearance--is a distressing and impairing disorder that usually begins during childhood or adolescence. With a chronic course, associated rates of social and academic impairment, and considerable cause of morbidity, adolescent BDD requires more clinical attention than it is currently given. The broad objective of this study is to increase knowledge about BDD, an understudied disorder in children and adolescents, by investigating its response to an SRI in a controlled fashion in this age group. Our specific research questions are:

1.      assess the efficacy and safety of fluoxetine vs. placebo in BDD and its delusional disorder variant

2.      explore whether delusionality (insight), the presence of comorbid major depression or obsessive compulsive disorder (OCD), and/or illness severity predicts response to fluoxetine.

Importance 

This study will provide much needed data for a population in great need of a reliable clinical treatment; pediatric BDD has received virtually no investigation and the symptoms of BDD can be debilitating, leading to psychiatric hospitalization and suicide attempts. Pediatric-onset BDD appears to interfere with the developmental tasks of childhood and adolescence, and pediatric BDD has a more malignant course of illness than adult-onset BDD.

If you or your child are interested in participating in this study, please contact Emma Racine at 718-653-4859 ext 223 or eracine@montefiore.org 

Click here to log in